ProQR Therapeutics N.V. (PRQR)
NASDAQ: PRQR · Real-Time Price · USD
2.070
-0.020 (-0.96%)
At close: Sep 4, 2026, 4:00 PM EDT
2.045
-0.025 (-1.21%)
After-hours: Sep 4, 2026, 7:59 PM EDT
ProQR Therapeutics Revenue
ProQR Therapeutics had revenue of 8.76M EUR in the quarter ending June 30, 2026, with 120.35% growth. This brings the company's revenue in the last twelve months to 18.42M, up 7.49% year-over-year. In the year 2025, ProQR Therapeutics had annual revenue of 16.35M, down -16.36%.
Revenue (ttm)
18.42M EUR
Revenue Growth
+7.49%
P/S Ratio
13.88
Revenue / Employee
98,730 EUR
Employees
187
Market Cap
292.12M USD
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 16.35M | -3.20M | -16.36% |
| Dec 31, 2024 | 19.55M | 10.02M | 105.20% |
| Dec 31, 2023 | 9.53M | 5.17M | 118.51% |
| Dec 31, 2022 | 4.36M | 1.98M | 83.31% |
| Dec 31, 2021 | 2.38M | -7.07M | -74.84% |
| Dec 31, 2020 | 9.45M | 7.52M | 388.98% |
| Dec 31, 2019 | 1.93M | -3.83M | -66.45% |
| Dec 31, 2018 | 5.76M | 4.27M | 285.35% |
| Dec 31, 2017 | 1.50M | -333.00K | -18.22% |
| Dec 31, 2016 | 1.83M | -1.41M | -43.49% |
| Dec 31, 2015 | 3.24M | 2.92M | 933.55% |
| Dec 31, 2014 | 313.00K | 197.00K | 169.83% |
| Dec 31, 2013 | 116.00K | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Fulcrum Therapeutics | 80.00M |
| Clinuvel Pharmaceuticals | 65.05M |
| Bicycle Therapeutics | 61.21M |
| Foghorn Therapeutics | 36.74M |
| Orchestra BioMed Holdings | 31.98M |
| AC Immune | 21.67M |
| Alector | 13.86M |
| Fate Therapeutics | 6.49M |
PRQR News
- 4 days ago - ProQR to Participate in Upcoming Investor Conferences in September 2026 - GlobeNewsWire
- 17 days ago - ProQR Therapeutics initiated with a Buy at BofA - TheFly
- 24 days ago - ProQR Announces Second Quarter 2026 Operating and Financial Results - GlobeNewsWire
- 24 days ago - ProQR Therapeutics Earnings release: Q2 2026 - Filings
- 2 months ago - ProQR Therapeutics registers to sell 3.03M ordinary shares for holders - TheFly
- 2 months ago - ProQR Therapeutics Registration statement: Registration filing - Filings
- 2 months ago - ProQR Therapeutics price target lowered to $10 from $14 at Raymond James - TheFly
- 2 months ago - ProQR Therapeutics price target lowered to $10 from $11 at JonesResearch - TheFly